Is pomalidomide a chemotherapy drug or a targeted therapy drug?

Pomalidomide, as a cancer-targeted drug, plays an important role in the treatment of multiple myeloma. Multiple myeloma is a malignant tumor originating from plasma cells in the bone marrow. Its abnormal proliferation and accumulation can lead to a series of serious complications such as bone destruction, anemia, and renal damage. Pomalidomide can precisely act on tumor cells and inhibit the growth and spread of tumors through multiple mechanisms.

First, pomalidomide can prevent the development of myeloma cells, thereby inhibiting the proliferation of tumor cells. This mechanism of action makes pomalidomide excellent in controlling multiple myeloma. Secondly, pomalidomide also has anti-angiogenic effects. By inhibiting the growth of new blood vessels, it cuts off the nutrient supply and oxygen supply to tumor cells, further weakening the tumor's ability to grow and survive. This dual mechanism of action makes pomalidomide one of the effective drugs for the treatment of multiple myeloma.

Compared with chemotherapy drugs, pomalidomide, as a targeted therapy drug, has higher selectivity and fewer side effects. It can precisely act on tumor cells while causing relatively little damage to normal cells. This allows patients to better tolerate the drug and improve their quality of life when receiving pomalidomide treatment.

However, pomalidomide may also cause some side effects during use, such as gastrointestinal reactions, fatigue, and blood system abnormalities. When receiving pomalidomide treatment, patients should pay close attention to their physical condition and perform necessary monitoring and treatment under the guidance of a doctor.

In summary, pomalidomide, as a targeted therapy, plays an important role in the treatment of multiple myeloma. It effectively inhibits the growth and spread of tumors by preventing the development of myeloma cells and anti-angiogenesis and other mechanisms, bringing new treatment hope to patients.

xa0

Reference materials:https://www.cancerresearchuk.org/about-cancer/treatment/drugs/pomalidomide-dexamethasone